Viewing Protocol Section

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Main Search All Studies All Organizations Report Bug
Viewing Protocol Section

Thank You for evaluating our software.

Clinical Trials

To give you an idea of how we make custom software. We have taken all of the Clinical Trials Information from our Federal Government(https://clinicaltrials.gov/).

The JSON File Structure of the files is as follows: Full Study -> Study => Sections => Modules. You are currently viewing a Protocol Section and its Modules.

We give the table structure here to give you an idea of what you are looking at. We put the explanation to the left and the data to the right.

A Protocol Section has the following Modules.

1. Identification Module

2. Status Module

3. Sponsor Collaborators Module

4. Oversight Module

5. Description Module

6. Conditions Module

7. Design Module

8. Arms Interventions Module

9. Outcomes Module

10. Eligibility Module

11. Contacts Locations Module

12. References Module

13. IPD Sharing Statement Module

Viewing Protocol Section

Study NCT00085709
Ignite Creation Date: 2024-05-05 @ 11:34 AM
Last Modification Date: 2024-10-26 @ 9:10 AM
Study NCT ID: NCT00085709
Protocol Section: NCT00085709
Start Identification Module Data
Expand Identification Module Data
Brief Title: S0106 Cytarabine and Daunorubicin w or wo Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML
Official Title: A Phase III Study of the Addition of Gemtuzumab Ozogamicin Mylotarg During Induction Therapy Versus Standard Induction With Daunomycin and Cytosine Arabinoside Followed by Consolidation and Subsequent Randomization to Post-Consolidation Therapy With Gemtuzumab Ozogamicin Mylotarg or No Additional Therapy For Patients Under Age 61 With Previously Untreated De Novo Acute Myeloid Leukemia AML
Acronym: None
Organization: SWOG Cancer Research Network
Organization Class: NETWORK
Organization Study ID: S0106
Secondary IDs
Secondary ID Type Domain Link
S0106 OTHER SWOG httpsreporternihgovquickSearchU10CA032102
U10CA032102 NIH None None
Start Status Module Data
Status Verified Date: 2015-09
Overall Status: COMPLETED
Study First Submit Date:
Study First Submit QC Date:
Last Update Submit Date:
Status:
Start Sponsor Collaborators Module Data
Investigator:
Lead Sponsor: SWOG Cancer Research Network
Lead Sponsor Class: NETWORK
Lead Sponsor: SWOG Cancer Research Network
Start Oversight Module Data
Description Module:
Study Last Update Post Date Type(Status Module):
Attachment: Upload